To study pancreatic, breast and small-cell lung cancers, Sunshine Biopharma Inc., of Montreal, has initiated studies of Adva-27a, designed to shrink tumors, in xenograft mice with tumors. Adva-27a is a GEM-difluorinated C-glycoside derivative of podophyllotoxin and is designed to inhibit the enzyme topoisomerase II.